To the Editor In their multicenter cohort study published recently in JAMA Oncology, Samadder et al1 analyzed a gene panel of 2984 unselected patients with solid tumors. They identified pathogenic germline variants (PGVs) in 397 patients and concluded that this approach identified more PGV carriers than current guidelines for germline cancer genetic testing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Colas C, De Pauw A, Golmard L. Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer. JAMA Oncol. 2021;7(7):1071. doi:10.1001/jamaoncol.2021.1005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.